Literature DB >> 28730569

Immune Escape Mechanism is Impaired in the Microenvironment of Thyroid Lymph Node Metastasis.

Lucas Leite Cunha1, Suely Nonogaki2, Fernando Augusto Soares3, José Vassallo3,4, Laura Sterian Ward5,6.   

Abstract

We previously identified the infiltration of CD8+ lymphocytes and COX2 expression as an independent factor of risk for recurrence in papillary thyroid carcinoma (PTC) patients. However, the presence of lymph node (LN) metastasis at diagnosis lost its significance in a multivariate model analysis. These results encouraged us to compare the immune cells arrangement in the microenvironment of the LN metastasis and the primary tumor. We studied 104 consecutive PTC patients. Tissue specimens of both primary tumor and LN metastasis at the time of diagnosis were available in 19 out of them. These 19 patients were followed up for 32 to 81 months (64.7 ± 47.5 months). Immune cell markers were investigated using immunohistochemistry and included tumor infiltrating lymphocytes subsets such as CD3, CD4, CD8, CD16, CD20, CD45RO, GRANZYME B, CD69, and CD25. We also investigated the expression of COX2 in tumor cells. Paired t test showed an increase of GRANZYME-B+ lymphocytes density in LN metastasis compared to the corresponding primary tumor, suggesting that LN metastasis is enriched with activated immune cells. In addition, we observed a decrease in COX2 expression levels in LN metastasis compared to the corresponding primary tumors, reinforcing the idea that the immune escape mechanism is impaired in the microenvironment of thyroid LN metastasis. In conclusion, our data demonstrated that the microenvironment of PTC LN metastasis present features that favor an anti-tumor immune response. This may help to explain why the presence of LN metastasis at diagnosis is not a good predictor of PTC patients' survival or disease progression.

Entities:  

Keywords:  Immune escape; Immune microenvironment; Lymph node metastasis; Papillary thyroid carcinoma

Mesh:

Year:  2017        PMID: 28730569     DOI: 10.1007/s12022-017-9495-2

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  7 in total

1.  CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer.

Authors:  Lucas Leite Cunha; Marjory Alana Marcello; Suely Nonogaki; Elaine Cristina Morari; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Clin Endocrinol (Oxf)       Date:  2014-09-22       Impact factor: 3.478

2.  Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer.

Authors:  Jena D French; Gregory R Kotnis; Sherif Said; Christopher D Raeburn; Robert C McIntyre; Joshua P Klopper; Bryan R Haugen
Journal:  J Clin Endocrinol Metab       Date:  2012-03-30       Impact factor: 5.958

3.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

4.  Is minimal residual lymph node disease in papillary thyroid cancer of prognostic impact? An analysis of the epithelial cell adhesion molecule EpCAM in lymph nodes of 40 pN0 patients.

Authors:  Alexander Rehders; Martin Anlauf; Ilona Adamowsky; Markus H Ghadimi; Sarah Klein; Christina Antke; Kenko Cupisti; Nikolas H Stoecklein; Wolfram T Knoefel
Journal:  Pathol Oncol Res       Date:  2013-08-06       Impact factor: 3.201

5.  Clinical utility of KAP-1 expression in thyroid lesions.

Authors:  Mariana Bonjiorno Martins; Marjory Alana Marcello; Elaine Cristina Morari; Lucas Leite Cunha; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Endocr Pathol       Date:  2013-06       Impact factor: 3.943

6.  Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation.

Authors:  Lucas Leite Cunha; Marjory Alana Marcello; Elaine Cristina Morari; Suely Nonogaki; Fábio Frangiotti Conte; René Gerhard; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Endocr Relat Cancer       Date:  2013-02-18       Impact factor: 5.678

7.  Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.

Authors:  Nune Markosyan; Edward P Chen; Rebecca A Evans; Victoire Ndong; Robert H Vonderheide; Emer M Smyth
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

  7 in total
  4 in total

1.  Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes.

Authors:  Zhigang Wang; Wei Liu; Chong Chen; Xiaolin Yang; Yunping Luo; Bailin Zhang
Journal:  Sci Rep       Date:  2019-01-22       Impact factor: 4.379

2.  Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links.

Authors:  Oksana Sulaieva; Oleksii Selezniov; Dmytro Shapochka; Nataliia Belemets; Oleksandr Nechay; Yelizaveta Chereshneva; Dibakhan Tsomartova; Marina Ivanova
Journal:  Heliyon       Date:  2020-01-08

3.  The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer.

Authors:  Wenli Liu; Lisha Sun; Juan Zhang; Wengang Song; Mingcheng Li; Hong Wang
Journal:  Biosci Rep       Date:  2021-04-30       Impact factor: 3.840

4.  Immune-related key gene CLDN10 correlates with lymph node metastasis but predicts favorable prognosis in papillary thyroid carcinoma.

Authors:  Zhaolan Xiang; Cheng Zhong; Aoshuang Chang; Junjun Ling; Houyu Zhao; Wei Zhou; Xianlu Zhuo
Journal:  Aging (Albany NY)       Date:  2020-02-11       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.